Endometrial Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

The Endometrial Cancer Pipeline Insight, 2026 highlights a robust landscape with more than 50 companies and over 55 pipeline drugs actively advancing in endometrial cancer. Key takeaways include several phase studies announced in May 2026: on May 28, Daiichi Sankyo began a phase 3 trial comparing T-DXd with standard chemotherapy, with or without radiotherapy, as adjuvant treatment for HER2-expressing endometrial cancer. On May 22, Merck Sharp & Dohme started a phase 3 study to see if sac-TMT with pembrolizumab improves survival compared with pembrolizumab alone. On May 20, AstraZeneca initiated a Phase III trial of puxitatug samrotecan versus physician's choice in advanced/metastatic disease, and BioNTech unveiled a two-cohort phase III program guided by HER2 expression. DelveInsight's report also notes more than 50 active players and 55 pipeline therapies, underscoring a lively ecosystem.